Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections
- 25 April 2007
- journal article
- case report
- Published by Wiley in Transplant Infectious Disease
- Vol. 9 (2) , 89-96
- https://doi.org/10.1111/j.1399-3062.2007.00208.x
Abstract
We describe the clinical courses of 3 patients with hematologic malignancies (2 with acute myelogenous leukemia and 1 with multiple myeloma) who developed invasive fungal infections due to uncommon molds (Alternaria spp., Paecilomyces lilacinus, and Zygomycetes). Breakthrough invasive fungal infections of the sinus (n=1), lung (n=3), and pericardium (n=1) developed despite fluconazole prophylaxis and failed to respond to treatment with other licensed antifungal therapies, including amphotericin B (n=3), caspofungin (n=2), and voriconazole (n=3), and surgical intervention (n=2). Salvage therapy with posaconazole oral suspension resulted in successful outcomes in all 3 patients, who subsequently underwent allogeneic hematopoietic stem cell transplantation (HSCT) while on continued posaconazole therapy. The median duration of posaconazole treatment before HSCT was 5 months (range: 1.5-6 months). Posaconazole salvage therapy allowed successful allogeneic HSCT in 3 patients with refractory invasive mold infections.Keywords
This publication has 35 references indexed in Scilit:
- In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and YeastsAntimicrobial Agents and Chemotherapy, 2006
- Refractory Coccidioidomycosis Treated with PosaconazoleClinical Infectious Diseases, 2005
- Disseminated zygomycosis post allogeneic bone marrow transplantationAmerican Journal of Hematology, 2005
- Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipientThe Journal of Heart and Lung Transplantation, 2004
- Disposition of Posaconazole following Single-Dose Oral Administration in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2004
- In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance programDiagnostic Microbiology and Infectious Disease, 2004
- Treatment ofScedosporium apiospermumBrain Abscesses with PosaconazoleClinical Infectious Diseases, 2002
- Emerging fungal pathogens in patients with hematologic malignancies and marrow/stem-cell transplant recipientsSeminars in Respiratory Infections, 2002
- In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. and Cryptococcus neoformansAntimicrobial Agents and Chemotherapy, 2001
- Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant RecipientsClinical Infectious Diseases, 2001